Abstract
Respiratory syncytial virus (RSV) is one of the leading causes of range of symptoms from mild upper to serious lower respiratory virus infections in infants, immunocompromised individuals, and the elderly. Despite many decades of research and development, a licensed RSV vaccine is not available for use in human. Since the RSV F and G proteins induce neutralizing antibodies and confer protection from infection, they are important for understanding disease and for developing vaccines and access to purified, expressed proteins is important to RSV research and diagnostics. We describe methods to produce recombinant RSV F and G proteins in human cells and purify these proteins using Ni Sepharose affinity chromatography.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Collins PL, Melero JA (2011) Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 162:80–99
Geevarghese B, Simoes EA. (2012) Antibodies for prevention and treatment of respiratory syncytial virus infections in children. Antivir Ther 17:201-211
Miao C, Radu GU, Caidi H, Tripp RA, Anderson LJ, Haynes LM (2009) Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice. J Gen Virol 90:1119–1123
Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, Zeitlin L (2014) Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A 111:5992–5997
Krusat T, Streckert HJ (1997) Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Arch Virol 142:1247–1254
Tripp R, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ (2001) CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2:732–738
Walsh EE, Brandriss MW, Schlesinger JJ (1985) Purification and characterization of the respiratory syncytial virus fusion protein. J Gen Virol 66:409–415
Wertz GW, Krieger M, Ball LA (1989) Structure and cell surface maturation of the attachment glycoprotein of human respiratory syncytial virus in a cell line deficient in O glycosylation. J Virol 63:4767–4776
Collins PL, Mottet G (1992) Oligomerization and post-translational processing of glycoprotein G of human respiratory syncytial virus: altered O-glycosylation in the presence of brefeldin A. J Gen Virol 73:849–863
Lambert DM (1988) Role of oligosaccharides in the structure and function of respiratory syncytial virus glycoproteins. Virology 164:458–466
Pastey MK, Samal SK (1997) Analysis of the bovine respiratory syncytial virus fusion protein (F) using monoclonal antibodies. Vet Microbiol 58:175–185
Anderson LJ, Hierholzer JC, Tsou C, Hendry RM, Fernie BF, Stone Y, McIntosh K (1985) Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 151:626–633
Mufson MA, Orvell C, Rafnar B, Norrby E (1985) Two distinct subtypes of human respiratory syncytial virus. J Gen Virol 66:2111–2124
Gimenez HB, Hardman N, Keir HM, Cash P (1986) Antigenic variation between human respiratory syncytial virus isolates. J Gen Virol 67:863–870
Peret TC, Hall CB, Schnabel KC, Golub JA, Anderson LJ (1998) Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol 79:2221–2229
Collins PL, Melero JA (2011) Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 162:80–99
Routledge EG, Willcocks MM, Samson AC, Morgan L, Scott R, Anderson JJ, Toms GL (1988) The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice. J Gen Virol 69:293–303
Roberts SR, Lichtenstein D, Ball LA, Wertz GW (1994) The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons. J Virol 68:4538–4546
Roder C, Krusat T, Reimers K, Werchau H (2000) Purification of respiratory syncytial virus F and G proteins. J Chromatogr B Biomed Sci Appl 737:97–106
Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59–74
Harrison T, Graham F, Williams J (1977) Host-range mutants of adenovirus type 5 defective for growth in HeLa cells. Virology 77:319–329
Acknowledgement
This work was supported by research funding from Emory University to Dr. Larry Anderson. RSV G plasmid available in the laboratory through a collaborative research program with Dr. A.G. Oomen’s laboratory was used for pilot experiment. We thank Dr. Paul Spearman and Dr. Xuemin Chen for providing 293F human cell line for pilot experimental purpose.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Jadhao, S.J., Anderson, L.J. (2016). Secretory Expression and Purification of Respiratory Syncytial Virus G and F Proteins in Human Cells. In: Tripp, R., Jorquera, P. (eds) Human Respiratory Syncytial Virus. Methods in Molecular Biology, vol 1442. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3687-8_5
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3687-8_5
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3685-4
Online ISBN: 978-1-4939-3687-8
eBook Packages: Springer Protocols